

(11) **EP 0 826 377 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**06.11.2002 Bulletin 2002/45**

(51) Int Cl.7: **A61K 49/00**

(21) Application number: **97306493.4**

(22) Date of filing: **26.08.1997**

(54) **Diagnostic agent for diabetes**

Diagnostisches Mittel für Diabetes

Agent diagnostique pour diabète

(84) Designated Contracting States:  
**DE ES FR GB IT SE**

(30) Priority: **27.08.1996 JP 22524396**  
**25.09.1996 JP 25304096**

(43) Date of publication of application:  
**04.03.1998 Bulletin 1998/10**

(73) Proprietor: **Tokyo Gas Co., Ltd.**  
**Tokyo 105-8527 (JP)**

(72) Inventors:  
• **Kohno, Tadashi**  
**Kawasaki-shi, Kanagawa 214-0011 (JP)**  
• **Hosoi, Isaburo**  
**Souka-shi, Saitama 340-0033 (JP)**  
• **Ohshima, Junko**  
**Yokohama-shi, Kanagawa 224-0006 (JP)**  
• **Shibata, Kunihiro**  
**Funabashi-shi, Chiba 274-0075 (JP)**

(74) Representative: **Harrison, David Christopher et al**  
**MEWBURN ELLIS**  
**York House**  
**23 Kingsway**  
**London WC2B 6HP (GB)**

(56) References cited:

- Chem. abstr., Vol. 82, No. 25, 23 June 1975 (Columbus, OH, USA), page 341, the abstract No. 168420d, LEFEBVRE, P. et al. "Naturally labeled carbon-13- labeled-glucose. Metabolic studies in human diabetes and obesity," Diabetes 1975, 24(2), 185-9.
- Chem. abstr., Vol. 87, No. 15, 10 October 1977 (Columbus, OH, USA), page 280, the abstract No. 113951a, LEFEBVRE, P. et al. "Sugars naturally labeled with carbon-13. Their interest for metabolic studies in man," Journ. Annu. Diabetol. Hotel-Dieu 1976, 187-94.
- Chem. abstr., Vol. 87, No. 7, 15 August 1977 (Columbus, OH, USA), page 182, the abstract No. 49735d, LEFEBVRE, P. et al. "Natural sugars labeled with carbon-13: interest in them for human metabolic studies," Med. Hyg. 1977, 35(1237), 1392-4.

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## Description

[0001] The present invention relates to a diagnostic agent for diabetes and in particular to a diagnostic agent for diabetes which comprises glucose labelled with  $^{13}\text{C}$  at a specific position, or pyruvic acid labelled with  $^{13}\text{C}$  at least one specific position.

[0002] Test methods generally used in the primary screening in diagnosis of diabetes are urine sugar test and fasting blood sugar levels test. These tests are simple and high in specificity, but are low in sensitivity and give negative results for patients with light diabetes, so 70 % or more patients are missed and these tests are considered inadequate as screening tests for diabetes (Sekikawa *et al.*, Medical Practice 10:63, 1993). On the one hand, a glucose tolerance test used for the diagnosis of diabetes brings about side effects due to administration of a large amount of glucose, and this test requires the restraint of a subject for several hours and repeated collection of blood, and imposes heavy physical burdens on the subject, and further the procedures are troublesome, so this test is actually impossible to carry out as a screening test of diabetes. Recently, blood HbA1C and fructosamine tests, which reflect average of blood sugar levels for a certain period in the past, have been introduced as screening tests of diabetes in some facilities. Under the existing circumstances, however, even those tests are cannot be said to be adequate in sensitivity and specificity for light diabetes, and there remain the problem of a difference in measurement results among facilities.

[0003] Blood sugar level, HbA1C and fructosamine tests have been used widely for diagnosis of the type of diabetes, management of outpatients with diabetes, and evaluation of therapeutic effects. However, blood sugar levels would drop at the time of fasting in the case of light diabetes, while besides the above-described problems, the HbA1C and fructosamine tests have the problem that the results of the tests cannot be known until a next visit to the hospital, so instructions would be given to the patient on the basis of the past test results.

[0004] Under such circumstances, there is demand for developments in a test method which is effective for patients even with light diabetes and non-invasive to the subjects and which give results immediately and accurately for diagnosis of diabetes, management of patients with diabetes and evaluation of therapeutic effects.

[0005] On the one hand, it is generally carried out to administer  $^{13}\text{C}$ -labeled glucose and measure  $^{13}\text{C}$  exhausting as carbon dioxide into an exhalation in order to assess energy expenditure. Because this analysis should be conducted under steady state, glucose should be administered for a long period before examination [J.J. Robert *et al.*, J. Appl. Physiol. 63, 1725-1732 (1987)]. Therefore, this analysis requires a long period for examination and imposes the heavy pains on the subject, and is thus practically not usable for diagnosis of diabetes.

[0006] It is reported that after naturally labelled  $^{13}\text{C}$ -glucose prepared from  $\text{C}_4$  plants is bolus administrated, the degree of exhalation of  $^{13}\text{CO}_2$  is reduced in the case of patients with diabetes [P. Lefebvre, *et al.*, Diabetologia 14, 39-45 (1978); M.J. Arnaud, *et al.*, Nutrition and the Diabetic Child, Pediat. Adolesc. Endocr. vol. 7, pp. 203-212, 1979]. However, because naturally labelled  $^{13}\text{C}$ -glucose have 6 carbons randomly labeled, we can scarcely evaluate an alternation of the metabolic pathway of glucose. Further, because the concentration of  $^{13}\text{C}$  in naturally labelled  $^{13}\text{C}$ -glucose is 2 % or thereabout, it is necessary to administer a large amount of glucose in order to monitor a change in the concentration of  $^{13}\text{CO}_2$  in an exhalation, and the burdens on the subject are therefore heavy.

[0007] The object of the present invention is to provide a diagnostic agent for diabetes to give accurate results immediately with as little disturbance as possible for the patient.

[0008] As a result of their research, the present inventors found that diabetes and its type can be accurately diagnosed by administering glucose labelled with  $^{13}\text{C}$  at a specific position or pyruvic acid labelled with  $^{13}\text{C}$  at least one specific position, and then determining degrees of increase of  $^{13}\text{C}$  levels in exhaled  $\text{CO}_2$ .

[0009] That is, the present invention relates to a diagnostic agent for diabetes comprising glucose labelled with  $^{13}\text{C}$  at a specific position.

[0010] The present invention further relates to a diagnostic agent for diabetes comprising pyruvic acid labelled with  $^{13}\text{C}$  at least one specific position.

[0011] In the drawings:

[0012] FIG. 1 shows the main metabolic pathway of glucose for decarboxylation (numbers in the brackets next to  $\text{CO}_2$  indicate the position of carbon in glucose).

[0013] FIG. 2 shows a method of sampling an exhalation from a rat.

[0014] FIG. 3 shows degrees of increase of  $^{13}\text{C}$  levels in exhaled  $\text{CO}_2$  ( $\Delta^{13}\text{C}$  (‰)) twenty minutes after intravenous injection of 1- $^{13}\text{C}$ -glucose (100 mg/kg).

[0015] FIG. 4 shows the relationship between the 1- $^{13}\text{C}$ -glucose breath test and fasting blood sugar levels.

[0016] FIG. 5 shows the relationship between the 1- $^{13}\text{C}$ -glucose breath test and the total amount of secreted insulin during the first 15 min.

[0017] FIG. 6 shows the relationship between the 3- $^{13}\text{C}$ -glucose breath test and fasting blood sugar levels.

[0018] FIG. 7 shows the time course of  $^{13}\text{C}$  levels in exhaled  $\text{CO}_2$  ( $\Delta^{13}\text{C}$  (‰)) during the 3- $^{13}\text{C}$ -glucose breath test.

[0019] FIG. 8 shows degrees of increase of  $^{13}\text{C}$  levels in exhaled  $\text{CO}_2$  ( $\Delta^{13}\text{C}$  (‰)) from 10 to 20 minutes after administration of 3- $^{13}\text{C}$ -glucose.

[0020] FIG. 9 shows the relationship between the 3-<sup>13</sup>C-glucose breath test and fructosamine levels in blood.

[0021] FIG. 10 shows the time course of <sup>13</sup>C levels in exhaled CO<sub>2</sub> ( $\Delta^{13}\text{C} (\text{‰})$ ) during the 2-<sup>13</sup>C-glucose breath test.

[0022] FIG. 11 shows the time course of <sup>13</sup>C levels in exhaled CO<sub>2</sub> ( $\Delta^{13}\text{C} (\text{‰})$ ) during the 6-<sup>13</sup>C-glucose breath test.

[0023] FIG. 12 shows the relationship between the 3-<sup>13</sup>C-pyruvate breath test and fasting blood sugar levels.

5 [0024] Hereinafter, embodiments of the present invention are described in detail.

[0025] The glucose in the present diagnostic agent for diabetes is glucose labelled with <sup>13</sup>C at a specific position, and the labelled position may be any of positions 1 to 6.

[0026] Glucose labelled with <sup>13</sup>C at a specific position includes e.g. commercial products such as 1-<sup>13</sup>C-glucose, 2-<sup>13</sup>C-glucose, 6-<sup>13</sup>C-glucose (produced respectively by EURISO-TOP Ltd., CIL Ltd., ISOTEC Ltd. and ICON Ltd.),  
10 3-<sup>13</sup>C-glucose (produced by CIL Ltd. and ICON Ltd.), 4-<sup>13</sup>C-glucose (produced by CIL Ltd.) and 5-<sup>13</sup>C-glucose (produced by CIL Ltd.).

[0027] The pyruvic acid in the present diagnostic agent for diabetes is pyruvic acid labelled with <sup>13</sup>C at least one specific position.

[0028] The pyruvic acid in the present invention may be any pyruvic acid in which one, two or three of carbons at positions 1 to 3 have been labelled with <sup>13</sup>C, preferably pyruvic acid labelled with <sup>13</sup>C at position 3. Specifically, commercial products such as sodium 3-<sup>13</sup>C-pyruvate (produced by ICON Ltd.) etc. can be used.

[0029] Because <sup>13</sup>C is a stable isotope, there is no danger of exposure to radiation, and examinations can be effected safely.

[0030] In examinations using the present diagnostic agent for diabetes, <sup>13</sup>C levels ( $\Delta^{13}\text{C} (\text{‰})$ ) in exhaled CO<sub>2</sub> just after administration are determined followed by evaluation of data on degrees of increase of <sup>13</sup>C levels in exhaled CO<sub>2</sub> ( $\Delta^{13}\text{C} (\text{‰})$ ) at predetermined intervals (e.g. 5 minutes, 20 minutes) after administration, or on time course (slope at the start, change in the slope, peak time etc.) of degrees of increase of <sup>13</sup>C in exhaled CO<sub>2</sub> ( $\Delta^{13}\text{C} (\text{‰})$ ) for a predetermined time after administration. Although the sole evaluation by this breath test is useful, the result of this test is preferably combined with blood sugar levels, fructosamine levels etc. for synthetic judgment.

25 [0031] <sup>13</sup>C levels in exhaled CO<sub>2</sub> can be determined using gas chromatography mass spectrometry (GC-MS), infra-red spectrophotometry, mass spectrometry, photoacoustic spectrophotometry and NMR (nuclear magnetic resonance).

[0032] The present diagnostic agent for diabetes can distinguish a group of diabetics from a normal group. In particular, the diagnostic agent for diabetes containing glucose labelled with <sup>13</sup>C can also distinguish the type of diabetes (whether diabetes is insulin dependent or independent).

30 [0033] Further, it is possible to obtain a material for evaluation, which depending on a difference in the position of carbon labelled with <sup>13</sup>C in glucose, is rendered special and advantageous to diagnosis of diabetes.

[0034] For example, glucose labelled with <sup>13</sup>C at position 1 (1-<sup>13</sup>C-glucose) can distinguish between members with diabetes and healthy members in a group with normal fasting blood sugar levels, so this glucose is advantageous to the primary screening. Further, by virtue of its excellent relationship to the total amount of insulin secreted, this glucose  
35 is used advantageously to determine a course of action for therapy. Glucose labelled with <sup>13</sup>C at position 3 (3-<sup>13</sup>C-glucose) can distinguish between patients with insulin-dependent diabetes and patients with insulin-independent type in the case of almost the same blood sugar levels, so this glucose is used advantageously for diagnosis of the type of diabetes. Moreover, this glucose may distinguish between the insulin-dependent diabetes and insulin-independent diabetes in the case of similar fructosamine levels, so it may be advantageously used for knowing an alternation in the disease (transition from the independent type to dependent type), which can be easily missed when evaluation is made  
40 using only fructosamine levels.

[0035] As shown in FIG. 1, carbons in glucose are decarboxylated in different metabolic pathways depending on their positions. Therefore, in cases where glucose labelled with <sup>13</sup>C at a specific position has been given, we can evaluate an alternation in the glucose metabolic pathways by determining the degree of exhalation of <sup>13</sup>CO<sub>2</sub>.

45 [0036] The present diagnostic agent for diabetes is manufactured into pharmaceutical preparations such as parenteral agents (tablets, capsules, powder, granules, liquid etc.), injections etc., depending on the administration route, by solely using glucose labelled with <sup>13</sup>C at a specific position (referred to hereinafter as labelled glucose) or pyruvic acid labelled with <sup>13</sup>C at least one specific position (referred to hereinafter as labelled pyruvic acid) or by mixing it with fillers or carriers. The fillers or carriers may be any of those conventionally used in this field if they are pharmaceutically acceptable. The type and composition of such preparations are altered suitably according to the route and method of administration. For example, water is used as a liquid carrier. As solid carriers, cellulose derivatives such as hydroxypropyl cellulose and organic acid salts such as magnesium stearate etc. are used. Water, physiological saline and various buffer solutions are generally desirable in the case of injections. Such preparations may be lyophilized for use as oral medicines, or the lyophilized preparations may be dissolved in suitable injection solvents e.g. liquids for intra-  
50 venous administration, such as sterilized water, physiological saline, electrolyte etc. just before use.

55 [0037] The content of the labelled glucose or labelled pyruvic acid in the pharmaceutical preparation varies according to the type of pharmaceutical preparation, and is usually in the range of 10 to 100 % by weight, preferably 50 to 100 % by weight. In the case of injections, for example, the substituted glucose or substituted pyruvic acid is added usually

in an amount of 1 to 40 % by weight. In the case of capsules, tablets, granules and powder, the content of the substituted glucose or substituted pyruvic acid is in the range of about 10 to 100 % by weight, preferably 50 to 100 % by weight, with the remainder being carriers.

[0038] The present diagnostic agent for diabetes should be administered at such a dosage as to enable confirmation of an increase of  $^{13}\text{C}$  levels in an exhalation after administration. Depending on the age and weight of the patient and the object of breath test, the dosage for each administration ranges from about 1 to 2000 mg/kg body weight in the case of an adult.

[0039] Hereinafter, the present invention is described in more detail by reference to Examples, which however are not intended to limit the scope of the invention.

## EFFECT OF THE INVENTION

[0040] According to the present invention, there is provided a diagnostic agent for diabetes which can be used safely without side effects and give accurate results immediately with less physical burdens on the subject. The present diagnostic agent for diabetes can not only distinguish between healthy persons and patients with diabetes even under the circumstances where the patients are easily missed, but can also determine the type of diabetes (insulin-dependent type or insulin-independent type).

## PREFERRED EMBODIMENTS OF THE INVENTION

[Test Example]

### [1] Materials and Methods

#### (1) Animals

[0041] Male Sprague-Dawley strain (SD) rats were purchased from Nippon Charles River K.K. Neonatal rats were purchased along with a lactating rat. The rats were bred at  $23^{\circ}\text{C} \pm 2^{\circ}\text{C}$  under  $55 \pm 10\%$  humidity before use. The rats were fed standard diet and water ad libitum.

#### (2) Generation of diabetic rats

[0042] For insulin-dependent diabetes, insulin-deficient type diabetes was generated in a matured rat by intraperitoneally administering of streptozotocin (STZ) ("Saibokogaku" (Cell Engineering), Extra Issue, Medical Experiment Manual Series, Strategy for Study of Diabetes, edited by Susumu Kiyono and Yoshikazu Oka, published by Shushunsha, Japan).

[0043] STZ (No. S-0130, a product of Sigma) was administered intraperitoneally at a dose of 90 mg/kg to the matured rat previously fasted overnight. Two days later, blood was collected from the tail vein, and its blood sugar level was determined using Terumo Mediac (blood sugar measurement set), and a rat with at least 400 mg/dl was selected from rats thus treated. STZ was dissolved in a citrate buffer (pH 4.5) and administered within 5 minutes after it was dissolved.

[0044] For insulin-independent diabetes, insulin secretion-deficient type diabetes was generated by administering streptozotocin (STZ) to neonatal rats ("Saibokogaku", Extra Issue, Medical Experiment Manual Series, Strategy for Study of Diabetes, edited by Susumu Kiyono and Yoshikazu Oka, published by Shushunsha, Japan).

[0045] STZ was subcutaneously administered at a dose of 90 mg/kg at 2 days old. At 4 days of age, blood was collected by cardiac puncture, and its blood sugar level was determined using Terumo Mediac (blood sugar measurement set), and a rat with at least 275 mg/dl was selected from rats thus treated. STZ was dissolved in a citrate buffer (pH 4.5) and administered within 5 minutes after it was dissolved.

#### (3) $^{13}\text{C}$ breath test

[0046] A rat fasted overnight was anesthetized by intraperitoneal administration of Nembutal (50 mg/kg) and fixed as shown in FIG. 2. Blood was collected from the tail vein, and its sugar level was determined using Terumo Mediac (blood sugar measurement set). 100 mg/kg  $^{13}\text{C}$ -glucose or sodium  $^{13}\text{C}$ -pyruvate (0.1 g/ml) dissolved in physiological saline was administered via the femoral vein, and the head was covered with a cylindrical tube, and its exhalation was sucked into a carbon dioxide meter CAPSTAR-100 (CWE, Inc.). An exhalation was collected in an volume of about 25  $\mu\text{l}$  for each measurement through a Hamilton syringe (FIG. 2). The flow rate of the carbon dioxide meter was controlled such that its carbon dioxide level was within the range of  $3.5 \pm 0.5\%$ . The  $^{13}\text{C}$  level in exhaled  $\text{CO}_2$  was determined in

a gas chromatography mass spectrophotometer (GC-MS). The analytical conditions for GC-MS are as follows:

[GC-MS conditions]	
Apparatus	Shimadzu GC-MS QP-5000 [Shimadzu Co., Ltd.].
Column	0.32 mm×25 m (ID×L) fused silica capillary column.
Ionization method	EI (electron impact) method.
Gasification chamber temperature	60 °C.
Column temperature	60 °C.
GC interface temperature	230 °C.
Carrier gas	He.
Carrier gas pressure	20 Kpa.
Measurement mode	SIM (selected ion monitoring).
Measurement ions	m/z = 45, 46, 47.
Sample injection volume	20 µl.

[0047] <sup>13</sup>C-glucoses used were 1-<sup>13</sup>C-glucose (<sup>13</sup>C purity of carbon at the 1-position: 99 atom-%, a product of EURISO-TOP Ltd. or CIL Ltd.), 2-<sup>13</sup>C-glucose (<sup>13</sup>C purity of carbon at the 2-position: 99 atom-%, a product of ISOTEC Ltd.), 3-<sup>13</sup>C-glucose (<sup>13</sup>C purity of carbon at the 3-position: 99 atom-%, a product of ICON Ltd.), and 6-<sup>13</sup>C-glucose (<sup>13</sup>C purity of carbon at the 6-position: 99 atom-%, a product of CIL Ltd. or ICON Ltd.). <sup>13</sup>C-pyruvic acid used was sodium 3-<sup>13</sup>C-pyruvate (<sup>13</sup>C purity of carbon at the 3-position: 99 atom-%, a product of ICON Ltd.). The rectum temperature was monitored through the experiment, and the body temperature was kept at 37 °C on a warming mat. After the experiment was finished, whole blood was collected from the abdominal aorta and used as a sample for measurement of fructosamine levels in blood. The analysis of fructosamine was entrusted to BML Ltd. After collection of blood, the rat used in the experiment was killed by administering an excess anesthetic.

[Method of calculating <sup>13</sup>C levels]

[0048] The ratio of the presence of an oxygen isotope in a sample was assumed to be the ratio found in nature, and its <sup>13</sup>C level was calculated from the ion peak areas of m/z = 45, 46 in the following formula. The ratio in areas of m/z = 45, 46 (A45/A46) was assumed to be "a" according to Japanese Patent LOP Publication No. 120434/95.

$$^{13}\text{C level (\%)} = \{(0.004176 - 0.0007462a)/(0.9944396 + 0.0034298a)\} \times 100 \quad (\text{Formula 1})$$

[Δ<sup>13</sup>C (‰) calculation method]

[0049] Calculated from <sup>13</sup>C level in exhaled CO<sub>2</sub> (<sup>13</sup>C t min.) and <sup>13</sup>C level in CO<sub>2</sub> standard gas (<sup>13</sup>C std) at each point in the following formula:

$$\Delta^{13}\text{C level (\%)} = \{(^{13}\text{C t min.} - ^{13}\text{C 0 min.})/^{13}\text{C std}\} \times 1000 \quad (\text{Formula 2})$$

## (4) Measurement of insulin levels in blood

[0050] A by-path was formed by cannulation between the femoral artery and femoral vein in a rat previously fasted overnight under anesthesia by intraperitoneal administration of Nembutal (50 mg/kg). The by-path was provided with a branch through which heparin (No. 15077-019, a product of GIBCO. BRL) was administered (100 U/rat). After  $^{13}\text{C}$ -glucose (0.1 g/ml) dissolved in physiological saline was administered (100 mg/kg) through the branch, blood was collected with time and examined for blood sugar levels and insulin levels. The insulin levels were determined using an insulin measurement kit (a product of Morinaga Seikagaku Kenkyusho, Japan).

## [2] Results

(1)  $1\text{-}^{13}\text{C}$ -glucose breath test ①

[0051] Animals examined were male Sprague-Dawley strain (SD) normal rats (four 8-week-old rats and four 11-week-old rats), male SD rats with insulin-independent diabetes (four 8-week-old rats and four 11-week-old rats), and male SD rats with insulin-dependent diabetes (four 8-week-old rats, four 9-week-old rats, and four 11-week-old rats; STZ was administered when the rats were 7-week-old). FIG. 3 shows the results of the measurement of degrees of increase of  $^{13}\text{C}$  levels in exhaled  $\text{CO}_2$  ( $\Delta^{13}\text{C}$  (‰)) at 20 minutes after intravenous injection of 100 mg/kg  $1\text{-}^{13}\text{C}$ -glucose. FIG. 4 shows the results of the measurement of degrees of increase of  $^{13}\text{C}$  levels in exhaled  $\text{CO}_2$  ( $\Delta^{13}\text{C}$  (‰)) at 20 minutes after intravenous injection of 100 mg/kg  $1\text{-}^{13}\text{C}$ -glucose, versus blood sugar levels just before administration of the glucose.

[0052] The distribution of  $\Delta^{13}\text{C}$  levels at 20 minutes after administration (FIG. 3) showed high levels over about 125 ‰ in the normal rats while low levels below about 125 ‰ in the rats with insulin-dependent diabetes and the rats with insulin-independent diabetes. It is assumed that in the case of higher sugar levels before administration, the degree of dilution of administered  $1\text{-}^{13}\text{C}$ -glucose in blood is rendered higher, thus decreasing the degree of discharge of  $^{13}\text{C}$  into an exhalation. Actually, it is observed that  $\Delta^{13}\text{C}$  levels decrease as blood sugar levels increase (FIG. 4). In the normal fasting blood sugar range (about 100 mg/dl), however, the  $\Delta^{13}\text{C}$  levels in the animals with diabetes are lower than those of the normal animals even although both of them have almost the same fasting blood sugar levels (FIG. 4). Therefore, it can be said that the  $1\text{-}^{13}\text{C}$ -glucose breath test does not only mean the degree of dilution of administered  $1\text{-}^{13}\text{C}$ -glucose, that is, blood sugar levels.

[0053] As exemplified above, the  $1\text{-}^{13}\text{C}$ -glucose breath test can distinguish between diabetes and normal in the same group with normal fasting blood sugar levels, and can thus serve as an accurate and superior primary screening method.

(2)  $1\text{-}^{13}\text{C}$ -glucose breath test ②

[0054] Animals examined were male SD normal rats (five 11-week-old rats) and male SD rats with insulin-independent diabetes (five 11-week-old rats). The  $1\text{-}^{13}\text{C}$ -glucose breath test and the measurement of insulin levels in blood were carried out in the same rats. 100 mg/kg of  $1\text{-}^{13}\text{C}$ -glucose was administered into the rats through the branch of the by-path provided between the femoral artery and femoral vein. Blood was collected before administration and at 1, 2, 3, 5, 7, 10 and 15 minutes after administration, and insulin levels in blood were determined. FIG. 5 shows the total amount of insulin secreted for the 15 minutes after administration versus the determined increase of  $^{13}\text{C}$  levels in exhaled  $\text{CO}_2$ .

[0055] Because the  $\Delta^{13}\text{C}$  levels at 20 minutes after administration of the  $1\text{-}^{13}\text{C}$ -glucose is in good relation with the total amount of insulin secreted for the first 15 minutes (FIG. 5), it is considered that this breath test is also useful as an examination method for determining a course of action for therapy.

(3)  $3\text{-}^{13}\text{C}$ -glucose breath test ①

[0056] Animals examined were male SD normal rats (four 8-week-old rats and four 11-week-old rats), male SD rats with insulin-independent diabetes (four 8-week-old rats and four 11-week-old rats), and male SD rats with insulin-dependent diabetes (four 8-week-old rats, four 9-week-old rats, and four 11-week-old rats; STZ was administered when the rats were 7-week-old). FIG. 6 shows the results of increase of  $^{13}\text{C}$  levels in exhaled  $\text{CO}_2$  ( $\Delta^{13}\text{C}$  (‰)) at 20 minutes after intravenous injection of 100 mg/kg  $3\text{-}^{13}\text{C}$ -glucose, versus fasting blood sugar levels before administration of the glucose.

[0057] The distribution of  $\Delta^{13}\text{C}$  levels at 20 minutes after administration (FIG 6) indicates that owing to the influence of blood sugar levels before administration,  $\Delta^{13}\text{C}$  levels tend to decrease as blood sugar levels increase, as is the case with the  $1\text{-}^{13}\text{C}$ -glucose breath test. However, insulin-dependent diabetes group tends to show lower  $\Delta^{13}\text{C}$  levels compared with insulin-independent group, in spite of similar fasting blood sugar levels between both groups. Therefore,

this breath test is considered usable for the diagnosis of the type of diabetes in combination with the measurement of fasting blood sugar levels.

#### (4) 3-<sup>13</sup>C-glucose breath test ②

[0058] Animals examined were male SD normal rats (four 11-week-old rats), male SD rats with insulin-independent diabetes (six 11-week-old rats), and male SD rats with insulin-dependent diabetes (four 11-week-old rats; STZ was administered when the rats were 9-week-old).

[0059] FIG. 7 shows the results of increase of <sup>13</sup>C levels in exhaled CO<sub>2</sub> ( $\Delta^{13}\text{C}$  (‰)) at 5, 10, 15 and 20 minutes after intravenous injection of 100 mg/kg 3-<sup>13</sup>C-glucose. In the curves of  $\Delta^{13}\text{C}$  for the first 20 minutes after administration of 3-<sup>13</sup>C-glucose (FIG. 7), the slope of the curve from the rats with insulin-independent diabetes tends to decrease in the later half. The curves at 10 to 20 minutes after administration indicate the following tendency of the slopes: normal rats > rats with insulin-independent diabetes > rats with insulin-dependent diabetes (FIG. 8). Therefore, 3-<sup>13</sup>C-glucose breath test can be used for both diagnosis of diabetes and diagnosis of the type of diabetes.

#### (5) 3-<sup>13</sup>C-glucose breath test ③

[0060] Animals examined were male SD normal rats (four 8-week-old rats and four 11-week-old rats), male SD rats with insulin-independent diabetes (four 8-week-old rats and four 11-week-old rats), and male SD rats with insulin-dependent diabetes (four 8-week-old rats and four 11-week-old rats; STZ was administered when the rats were 7-week-old). FIG. 9 shows the results of increase of <sup>13</sup>C levels in exhaled CO<sub>2</sub> ( $\Delta^{13}\text{C}$  (‰)) and fructosamine levels in blood at 20 minutes after intravenous administration of 100 mg/kg 3-<sup>13</sup>C-glucose.

[0061] When  $\Delta^{13}\text{C}$  levels and fructosamine levels at 20 minutes after administration are plotted,  $\Delta^{13}\text{C}$  levels in the rats with insulin-dependent diabetes were lower than those in the rats with insulin-independent diabetes even though both of them have similar fructosamine levels (FIG. 9). Many reports have revealed that patients with symptoms of insulin-dependent diabetes at a first stage of the onset undergo transition to insulin-independent diabetes at a later stage. Depending on such change in symptoms, it is necessary to alter methods such as insulin treatment etc., but conventional tests for determining only average blood sugar levels in terms of fructosamine, HbA1c etc. can miss such change. Accordingly, the 3-<sup>13</sup>C-glucose breath test is also useful as a test for knowing such change in symptoms.

#### (6) 2-<sup>13</sup>C-glucose and 6-<sup>13</sup>C-glucose breath tests

[0062] Animals examined were male SD normal rats (two 8-week-old rats), male SD rats with insulin-independent diabetes (two 8-week-old rats), and male SD rats with insulin-dependent diabetes (two 8-week-old rats). FIG. 10 shows the time course of <sup>13</sup>C levels in exhaled CO<sub>2</sub> ( $\Delta^{13}\text{C}$  (‰)) for 40 minutes after intravenous injection of 2-<sup>13</sup>C-glucose. FIG. 11 shows the time course of <sup>13</sup>C levels in exhaled CO<sub>2</sub> ( $\Delta^{13}\text{C}$  (‰)) for 20 minutes after intravenous injection of 6-<sup>13</sup>C-glucose. Both of the 2-<sup>13</sup>C-glucose breath test (FIG. 10) and 6-<sup>13</sup>C-glucose breath test (FIG. 11) show that  $\Delta^{13}\text{C}$  levels in the rats with insulin-dependent diabetes are lower than those in the rats with insulin-independent diabetes, so both of the breath tests can be considered usable in diagnosis of the type of diabetes.

#### (7) 3-<sup>13</sup>C-pyruvate breath test

[0063] Animals examined were male Sprague-Dawley strain (SD) normal rats (four 8-week-old rats and four 11-week-old rats), male SD rats with insulin-independent diabetes (four 8-week-old rats and four 11-week-old rats), and male SD rats with insulin-dependent diabetes (four 8-week-old rats, four 9-week-old rats and four 11-week-old rats; STZ was administered when the rats were 7-week-old). FIG. 12 shows the results of an increase of <sup>13</sup>C levels in exhaled CO<sub>2</sub> ( $\Delta^{13}\text{C}$  (‰)) for 10 minutes after intravenous injection of 100 mg/kg sodium 3-<sup>13</sup>C-pyruvate and fasting blood sugar levels in the same rats just before administration of the pyruvate.

[0064]  $\Delta^{13}\text{C}$  levels in the rats with insulin-dependent diabetes that maintain high fasting blood sugar levels (blood sugar levels of not less than 200 mg/dl) are distributed in the wide range from 100 to 600 (‰). In the normal fasting blood sugar range of about 100 mg/dl, however, the normal rats show lower levels than about 400 (‰) while the rats with insulin-independent diabetes and the rats with insulin-dependent diabetes with fasting blood sugar levels of not more than 200 mg/dl show higher levels than about 400 (‰).

[0065] The fasting blood sugar test used for the primary screening in diagnosis of diabetes is considered to miss about 2/3 of patients with diabetes because their blood sugar levels are in the normal range. However, the present 3-<sup>13</sup>C-pyruvate exhalation test can distinguish between members with diabetes and normal members in the same group having normal fasting blood sugar levels, and can thus serve as an accurate and superior primary screening method.

[Pharmaceutical Preparation Example 1] (Injection)

[0066] 10 parts by weight of 1-<sup>13</sup>C-glucose was dissolved in 90 parts by weight of physiological saline and sterilized by filtration through a Millipore filter. The filtrate was introduced into a vial and sealed to give an injection.

[Pharmaceutical Preparation Example 2] (Internal liquid agent)

[0067] 10 parts by weight of 1-<sup>13</sup>C-glucose was dissolved in 90 parts by weight of de-ionized water and sterilized by filtration through a Millipore filter. The filtrate was introduced into a vial and sealed to give an internal liquid agent.

[Pharmaceutical Preparation Example 3] (Injection)

[0068] 10 parts by weight of sodium 3-<sup>13</sup>C-pyruvate was dissolved in 90 parts by weight of physiological saline and sterilized by filtration through a Millipore filter. The filtrate was introduced into a vial and sealed to give an injection.

[Pharmaceutical Preparation Example 4] (Internal liquid agent)

[0069] 10 parts by weight of sodium 3-<sup>13</sup>C-pyruvate was dissolved in 90 parts by weight of de-ionized water and sterilized by filtration through a Millipore filter. The filtrate was introduced into a vial and sealed to give an internal liquid agent.

## Claims

1. A diagnostic agent for diabetes, which comprises glucose labelled with <sup>13</sup>C at a specific position.
2. A diagnostic agent for diabetes according to claim 1, wherein the glucose is labelled with <sup>13</sup>C at position 1.
3. A diagnostic agent for diabetes according to claim 1, wherein the glucose is labelled with <sup>13</sup>C at position 3.
4. A diagnostic agent for diabetes, which comprises pyruvic acid labelled with <sup>13</sup>C at least at one specific position.
5. A diagnostic agent for diabetes according to claim 4, wherein the pyruvic acid is labelled with <sup>13</sup>C at position 3.
6. The use in the preparation of a composition for diagnosing diabetes of glucose or pyruvic acid labelled with <sup>13</sup>C.

## Patentansprüche

1. Mittel zur Diagnose von Diabetes, beinhaltend an einer bestimmten Position mit <sup>13</sup>C markierte Glucose.
2. Mittel zur Diagnose von Diabetes gemäß Anspruch 1, wobei die Glucose an Position 1 mit <sup>13</sup>C markiert ist.
3. Mittel zur Diagnose von Diabetes gemäß Anspruch 1, wobei die Glucose an Position 3 mit <sup>13</sup>C markiert ist.
4. Mittel zur Diagnose von Diabetes, beinhaltend an mindestens einer bestimmten Position mit <sup>13</sup>C markierte Brenztraubensäure.
5. Mittel zur Diagnose von Diabetes gemäß Anspruch 4, wobei die Brenztraubensäure an Position 3 mit <sup>13</sup>C markiert ist.
6. Verwendung von <sup>13</sup>C markierter Brenztraubensäure oder Glucose zur Herstellung einer Zusammensetzung zur Diagnose von Diabetes.

## Revendications


1. Agent de diagnostic pour le diabète, qui comprend du glucose marqué avec du <sup>13</sup>C à une position spécifique.



## EP 0 826 377 B1


2. Agent de diagnostic pour le diabète selon la revendication 1, dans lequel le glucose est marqué avec du  $^{13}\text{C}$  en position 1.
- 5 3. Agent de diagnostic pour le diabète selon la revendication 1, dans lequel le glucose est marqué avec du  $^{13}\text{C}$  en position 3.
4. Agent de diagnostic pour le diabète, qui comprend de l'acide pyruvique marqué avec du  $^{13}\text{C}$  à au moins une position spécifique.
- 10 5. Agent de diagnostic pour le diabète selon la revendication 4, dans lequel l'acide pyruvique est marqué avec du  $^{13}\text{C}$  en position 3.
- 15 6. Utilisation de glucose ou d'acide pyruvique marqué avec du  $^{13}\text{C}$  dans la préparation d'une composition pour le diagnostic du diabète.
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55

FIG.1



Main Metabolic Pathway of Glucose

FIG.2



Breath Sampling System from Rat

FIG.3




FIG.4

1-<sup>13</sup>C-Glucose Breath Test vs Fasting Blood Sugar




FIG.5

1-<sup>13</sup>C-Glucose Breath Test vs Total Amount  
of Secreted Insulin





FIG.6

3-<sup>13</sup>C-Glucose Breath Test  
vs Fasting Blood Sugar



- △ Normal
- Insulin-independent diabetes
- Insulin-dependent diabetes

FIG.7

Time Course of  $^{13}\text{CO}_2$  Exhalation  
during 3- $^{13}\text{C}$ -Glucose Breath Test






FIG.8

Increase of  $^{13}\text{CO}_2$  from 10 to 20 Minutes after :  
Administration of 3- $^{13}\text{C}$ -Glucose





FIG.9

3-<sup>13</sup>C-Glucose Breath Test vs Fructosamine Level  
in Blood



- Δ Normal
- ◻ Insulin-independent diabetes
- Insulin-dependent diabetes

FIG.10

Time Course of  $^{13}\text{CO}_2$  Exhalation during  
2- $^{13}\text{C}$ -Glucose Breath Test




FIG.11

Time Course of  $^{13}\text{CO}_2$  Exhalation during  
6- $^{13}\text{C}$ -Glucose Breath Test





FIG.12

3-<sup>13</sup>C-Pyruvate Breath Test vs Fasting  
Blood Sugar



- △ Normal
- ▣ Insulin-independent diabetes
- Insulin-dependent diabetes